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EDITORIAL
Post-exposure prophylaxis for hepatitis A:            
immune globulin, vaccine or both?
M.F. ALLAM
Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Cordoba, Spain
Hepatitis A (HAV) causes one of the most common 
infectious diseases in the world and may produce 
clinical conditions ranging from a-symptomatic in-
fection to acute liver failure. Hepatitis A infection 
is an endemic problem in most African and South 
American Countries, meanwhile its incidence has 
largely declined over the last 2 decades in Western 
Europe and USA [1, 2].
The traditional preventive measure for hepatitis A 
infection is passive immunization with immune glob-
ulin. According to recent recommendations, serum 
gamma globulin administration could be replaced by 
vaccinations for post-exposure prophylaxis because 
of the progressively lower anti-hepatitis A virus con-
tent of gamma globulin and the short duration of the 
protective effect [2-4].
Recently, Victor et al. [5] conducted two-arm clinical 
trail, in Kazakhstan, to compare hepatitis A vaccine 
with immune globulin for post-exposure prophylaxis 
to contacts of patients with hepatitis A. Of 4524 con-
tacts who underwent randomization, 1414 (31%) 
were susceptible to hepatitis A virus and 1090 were 
eligible for the per-protocol analysis. Among these 
contacts, 568 received hepatitis A vaccine and 522 
received immune globulin. Symptomatic infection 
with hepatitis A virus was confirmed in 25 contacts 
receiving vaccine (4.4%) and in 17 contacts receiv-
ing immune globulin (3.3%) (relative risk, 1.35; 
95% confidence interval, 0.70 to 2.67). The Authors 
concluded that both hepatitis A vaccine and immune 
globulin provided good protection after exposure, and 
hepatitis A vaccine may be a reasonable alternative to 
immune globulin for post-exposure prophylaxis.
I have deep concerns regarding the study conclusions 
and recommendations, especially that we can not gen-
eralize or at least apply these recommendations in the 
European Countries.
First, immune globulin provided better protection 
than hepatitis A vaccine, although without significant 
difference; 17 of 522 contacts vs 25 of 568 contacts 
developed clinical symptoms of hepatitis A plus IgM-
positive and ALT ≥ twice ULN respectively. This 
better protection was more clear on comparing the 
development of clinical and subclinical hepatitis A in 
contacts of hepatitis A patients; 35 of 522 contacts vs 
49 of 568 contacts respectively.
Second, contacts who received immune globulins and 
posteriorly developed hepatitis A had lower levels of 
ALT together with less GIT symptoms and jaundice 
compared with contacts who received hepatitis A vac-
cine and posteriorly developed hepatitis A. The sever-
ity of illness measured by ALT level at time of illness 
shows statistical significance; 725 ± 461 U/liter in 
contacts who received immune globulin vs. 1001 ± 397 
U/liter in contacts who received hepatitis A vaccine.
Third, previous studies showed that the efficacy of 
hepatitis A vaccine when time since exposure is pro-
longed (more than 1 week from onset of illness in the 
index case) is likely to be significantly lower than 
immune globulin. It is recommended for travellers 
to endemic areas to receive hepatitis A vaccine > 2 
weeks before leaving, meanwhile travellers leaving 
before day 14 should receive immune globulin plus 
vaccine [1, 6].
Finally, prescribing of hepatitis A vaccine rather than 
immune globulin could be cost effective in endemic 
areas, like Kazakhstan, where hepatitis A incidence 
is high [5]. Meanwhile in Western Countries where 
hepatitis A incidence is low or very low effectiveness 
overweight cost in post-exposure prophylaxis of hep-
atitis A. In Spain, where the incidence of hepatitis A 
is less than 2-9/100000 inhabitants in 2002-2004 [7], 
it is recommended to prescribe household contacts of 
index patients with hepatitis A immune globulin and 
hepatitis A vaccine simultaneously.
Key words
Postexposure • Prophylaxis • Hepatitis A • Immune globulin • Vaccine
J PREV MED HYG 2008; 49: 129-130
References
[1] Webster G, Barnes E, Dusheiko G, Franklin I. Protecting trav-
ellers from hepatitis A. Vaccine should be used for almost every 
occasion when prevention is required. BMJ 2001;322:1194–5.
[2] Gendrel D, Launay O, Moulin F, Larnaudie S, Hau I, Laurent 
C, et al. Prophylaxis for contacts of an index case of hepatitis 
A: immunoglobulins or vaccination? [Article in French] Presse 
Med 2007;36:1072-7.
[3] Bruguera M. Prevention of viral hepatitis [Article in Spanish]. 
Enferm Infecc Microbiol Clin 2006;24:649-56.
[4] Crowcroft NS. Protecting contacts of hepatitis A: what’s the 
difference between vaccine and human normal immunoglobu-
lin? Epidemiol Infect 2007;12:1-4.
M.F. ALLAM
130
[5] Victor JC, Monto AS, Surdina TY, Suleimenova SZ, 
Vaughan G, Nainan OV, et al. Hepatitis A Vaccine vs. Im-
mune Globulin for Postexposure Prophylaxis. N Engl J Med 
2007;357:1685-94.
[6] Steffen R, Gyurech D. Advances in hepatitis A prevention in 
travellers. J Med Virol 1994;44:460-2.
[7] Cilla G, Pérez-Trallero E, Artieda J, Serrano-Bengoechea E, 
Montes M, Vicente D. Marked decrease in the incidence and 
prevalence of hepatitis A in the Basque Country, Spain, 1986-
2004. Epidemiol Infect 2007;135:402-8.
■ Received on December 7, 2007. Accepted on June 16, 2008.
■ Correspondence: Mohamed Farouk Allam, Department of Pre-
ventive Medicine and Public Health, Faculty of Medicine, Uni-
versity of Cordoba, Av.da Menéndez Pidal s/n, Cordoba 14004, 
Spain - Tel. +34 957 218278 - Fax +34 957 218573 - E-mail: 
fm2faahm@uco.es
